Caussy Cyrielle, Johansson Lars
Univ Lyon CarMen Laboratory INSERM INRA INSA Lyon Université Claude Bernard Lyon 1 Pierre-Bénite France.
Hospices Civils de Lyon Département Endocrinologie Diabète et Nutrition Hôpital Lyon Sud Pierre-Bénite France.
Endocrinol Diabetes Metab. 2020 Apr 20;3(4):e00134. doi: 10.1002/edm2.134. eCollection 2020 Oct.
Nonalcoholic fatty liver disease is a growing epidemic affecting 30% of the adult population in the Western world. Its progressive form, nonalcoholic steatohepatitis (NASH), is associated with an increased risk of advanced fibrosis, cirrhosis and liver-related mortality. Therefore, the detection of NAFLD and risk stratification according to the severity of the disease is crucial for the management of patients with NAFLD. Liver biopsy for such risk stratification strategies is limited by its cost and risks; therefore, noninvasive alternatives have been developed. Among noninvasive biomarkers developed in NAFLD, magnetic resonance (MR)-based biomarkers have emerged as key noninvasive biomarkers in NAFLD with the ability to accurately detect hepatic steatosis and liver fibrosis. The potential utility of MRI for the detection of NASH and functional liver assessment has also recently emerged. In the current review, we will discuss the data supporting the utility of MR-based biomarker for the detection of features of NAFLD and its potential use in clinical practice and clinical research in NAFLD.
非酒精性脂肪性肝病是一种日益流行的疾病，影响着西方世界30%的成年人口。其进展型，即非酒精性脂肪性肝炎（NASH），与晚期纤维化、肝硬化及肝脏相关死亡率的风险增加有关。因此，检测非酒精性脂肪性肝病并根据疾病严重程度进行风险分层对于非酒精性脂肪性肝病患者的管理至关重要。用于此类风险分层策略的肝脏活检受到其成本和风险的限制；因此，已开发出非侵入性替代方法。在非酒精性脂肪性肝病中开发的非侵入性生物标志物中，基于磁共振（MR）的生物标志物已成为非酒精性脂肪性肝病中的关键非侵入性生物标志物，能够准确检测肝脂肪变性和肝纤维化。磁共振成像（MRI）在检测NASH和功能性肝脏评估方面的潜在效用最近也已显现。在本综述中，我们将讨论支持基于MR的生物标志物用于检测非酒精性脂肪性肝病特征的数据及其在非酒精性脂肪性肝病临床实践和临床研究中的潜在用途。
